Low-Dose Metronomic Chemotherapy: Myth or Truth?

Publisher： Karger

E-ISSN： 2296-5262|29|7|305-307

ISSN： 2296-5270

Source： Oncology Research and Treatment, Vol.29, Iss.7, 2006-07, pp. : 305-307

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

Bevacizumab plus Low-Dose Metronomic Oral Cyclophosphamide in Heavily Pretreated Patients with Recurrent Ovarian Cancer

By  

Oncology, Vol. 79, Iss. 1-2, 2010-11 ,pp. : 98-104

Karger

Access to resources Recommend Favorite

Antiangiogenic Metronomic Chemotherapy

By  

Oncology Research and Treatment, Vol. 31, Iss. 4, 2008-03 ,pp. : 161-162

Karger

Access to resources Recommend Favorite

Comparison of Low-Dose versus Standard-Dose Colony Stimulating Factor in Patients with Chemotherapy-Induced Febrile Neutropenia

By  

Oncology, Vol. 65, Iss. 3, 2003-12 ,pp. : 283-284

Karger

Access to resources Recommend Favorite

Hepatic Arterial Infusion Chemotherapy Using Low-Dose 5-Fluorouracil and Cisplatin for Advanced Hepatocellular Carcinoma

By  

Oncology, Vol. 78, Iss. 1, 2010-07 ,pp. : 148-153

Karger

Access to resources Recommend Favorite

Weekly Low-Dose Docetaxel in Advanced Hormone-Resistant Prostate Cancer Patients Previously Exposed to Chemotherapy

By  

Oncology, Vol. 64, Iss. 4, 2003-05 ,pp. : 300-305

Karger

Access to resources Recommend Favorite